STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results